Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

Abstract Background Immune checkpoint inhibitors (ICIs) have been approved as second‐line therapy for advanced non–small cell lung cancers (NSCLCs) progressing after platinum‐based chemotherapy. However, some patients' disease progressed rapidly and sometimes exhibited explosive tumor progressi...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Alain Vergnenegre, Margaux Geier, Florian Guisier, Regine Lamy, Bénédicte Comet, Gwenaelle Le Garff, Pascal Do, Henri Janicot, Hugues Morel, Chantal Decroisette, Michel Andre, Lionel Falchero, Nicolas Paleiron, Isabelle Monnet, the GFPC Team
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Wiley 2020-01-01
Σειρά:Cancer Medicine
Θέματα:
immune checkpoint inhibitors
non–small cell lung cancer
rapid progression
second‐line treatment
Διαθέσιμο Online:https://doi.org/10.1002/cam4.2716
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια